Crofelemer
Rare Diseases
Napo Pharmaceuticals, Inc.mixturePhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Rare Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Burosumab Bicetre Hospital | Phase 4 | BB |
Irinotecan Gradalis, Inc. | Phase 3 | B |
FILGRASTIM Hospices Civils de Lyon | Phase 2/3 | B |
GEMOGENOVATUCEL-T Gradalis, Inc. | Phase 3 | B |
Durvalumab Prisma Health-Upstate | Phase 2 | CCC |
View all 11 →
Same molecule, other indications
Crofelemer is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →